Avadel Pharmaceuticals has entered into an exclusive global license agreement with XWPharma to develop and commercialize valiloxybate, a novel treatment for sleep disorders.

Target Overview

Avadel Pharmaceuticals plc is a biopharmaceutical company committed to transforming medicines for improved patient outcomes. A leader in sleep medicine, Avadel focuses on innovative solutions for treating sleep disorders. The company has announced an exclusive global license agreement with XWPharma Ltd. to develop and commercialize valiloxybate, a GABAB receptor agonist. This drug is designed for a range of indications, particularly to address sleep disorders like narcolepsy and idiopathic hypersomnia (IH). Valiloxybate is distinctive as it is formulated to be taken once at bedtime and is both salt-free and devoid of artificial sweeteners, enhancing patient compliance and comfort.

By integrating valiloxybate into its portfolio, Avadel reinforces its position as an innovator in the domain of sleep disorders. CEO Greg Divis emphasized the significance of this addition, pointing to the success of their existing product, LUMRYZ, which has already demonstrated the benefits of a once-at-bedtime oxybate therapy. This strategic move aims to broaden the treatment landscape for patients dealing with hypersomnolence disorders.

Industry Overview

The landscape of sleep medicine is gaining increased focus as awareness of the impact of sleep disorders on overall health continues to grow. Disorders such as narcolepsy and idiopathic hypersomnia have received more attention due to t